CONFERENCE PROGRAM

Tuesday, January 15

4:00 p.m.-5:00 p.m.  WELCOME AND KEYNOTE SESSION
Salons AB
Strategies for targeted and immune therapy in melanoma
Meenhard Herlyn, The Wistar Institute, Philadelphia, PA

5:00 p.m.-6:30 p.m.  OPENING RECEPTION
Liberty Hall 2345

Wednesday, January 16

7:00 a.m.-8:00 a.m.  CONTINENTAL BREAKFAST
Liberty Hall 2345

8:00 a.m.-10:00 a.m.  SESSION 1: UNDERSTANDING RESISTANCE TO CHECKPOINT BLOCKADE
Salons AB
Session Chair: Antoni Ribas, UCLA Medical Center, Los Angeles, CA
Next targets for immune checkpoint blockade in melanoma
Hassane M. Zarour, UPMC Hillman Cancer Center, Pittsburgh, PA
Response and resistance to checkpoint blockade therapy
Antoni Ribas
Overcoming immune resistance with rationally designed combination
immunotherapy
Roberta Zappasodi, Memorial Sloan Kettering Cancer Center, New York, NY
A cancer cell program promotes T-cell exclusion and resistance to checkpoint
blockade*
Livnat Jerby-Arnon, The Broad Institute of MIT and Harvard, Cambridge, MA
Melanoma evolves complete immunotherapy resistance through acquisition of a
hypermetabolic phenotype*
Arthur J. Liu, The University of Texas MD Anderson Cancer Center, Houston, TX

10:00 a.m.-10:30 a.m.  BREAK
Grand Ballroom Foyer

*Short talk from proffered abstract.
10:30 a.m.-12:30 p.m.  
**SESSION 2: UNIQUE BIOLOGY OF MELANOMA**  
Salons AB  

**Session Chair: Michael A. Davies**, The University of Texas MD Anderson Cancer Center, Houston, TX  

**Distinct immune and molecular features of melanoma brain metastases**  
Michael A. Davies  

**Concepts of cancer and metastasis: Historical perspective**  
Claire Lugassy, Institut Curie, Paris, France  

**Impact of tumor-resident dendritic cells on antitumor immune responses**  
Stefani Spranger, MIT Koch Institute for Integrated Cancer Research, Cambridge, MA  

**Nongenomic BAP1 aberrancy drives highly aggressive cutaneous melanoma phenotype**  
Scott Woodman, The University of Texas MD Anderson Cancer Center, Houston, TX  

**Epigenetic silencing of CDR1as drives IGF2BP3-mediated melanoma invasion and metastasis**  
Douglas Hanniford, NYU Langone Health, New York, NY  

12:30 p.m.-2:30 p.m.  
**LUNCH ON OWN**  

2:30 p.m.-4:30 p.m.  
**SESSION 3: MELANOMA METABOLISM**  
Salons AB  

**Session Chair: Paul B. Chapman**, Memorial Sloan Kettering Cancer Center, New York, NY  

**Elevated endogenous SDHA drives pathologic metabolism in highly metastatic uveal melanoma**  
Chandrani Chattopadhyay, The University of Texas MD Anderson Cancer Center, Houston, TX  

**Tumor cell oxidative metabolism as a barrier to antitumor immunity in melanoma**  
Greg M. Delgoffe, University of Pittsburgh, Pittsburgh, PA  

**Targeting melanoma metabolism to overcome resistance to treatment**  
Paul B. Chapman  

**Unique lipid metabolite profiling in BRAF^{V600E} inhibitor drug-resistant melanoma and their potential as drug target**  
Meng-Ting Chang, Agricultural Biotechnology Research Center, Academia Sinica, Taipei, Taiwan  

**The glutaminase inhibitor CB-839 potentiates antimalanoma activity of standard-of-care targeted therapies and immunotherapies**  
Vashisht Yennu Nanda, The University of Texas MD Anderson Cancer Center, Houston, TX  

4:30 p.m.-7:00 p.m.  
**POSTER SESSION A AND RECEPTION**  
Liberty Hall 2345  

*Short talk from proffered abstract.*
CONFERENCE PROGRAM

Thursday, January 17

7:00 a.m.-8:00 a.m.  CONTINENTAL BREAKFAST
Liberty Hall 2345

8:00 a.m.-10:00 a.m.  SESSION 4: EARLY MELANOMA DETECTION AND PREVENTION
Salons AB

Session Chair: Sancy A. Leachman, Oregon Health & Science University, Portland, OR

The War on Melanoma: Oregon’s early detection experiment
Sancy A. Leachman

Preventing melanoma progression through a genomic approach
Marianne Berwick, University of New Mexico Health Sciences Center-Albuquerque, Albuquerque, NM

Opportunities and challenges in melanoma early detection
David Polsky, New York University Langone Medical Center, New York, NY

The role of keratinocyte desmoglein 1 in shaping the melanoma tumor niche*
Hope E. Burks, Northwestern University, Feinberg School of Medicine, Chicago, IL

Identifying the molecular and environmental factors mediating transformation of melanocyte stem cells to melanoma*
Andrew C. White, Cornell University, Ithaca, NY

10:00 a.m.-10:30 a.m.  BREAK
Grand Ballroom Foyer

10:30 a.m.-12:30 p.m.  SESSION 5: NONCUTANEOUS MELANOMA AND RARE CUTANEOUS SUBTYPES
Salons AB

Session Chair: Richard D. Carvajal, Columbia University Medical Center, New York, NY

Immunosensitivity and resistance in advanced uveal melanoma
Richard D. Carvajal

Novel genomic and transcriptomic aberrations in acral compared to sun-exposed melanomas
Ruth Halaban, Yale University, New Haven, CT; Farshad Farshidfar, Stanford University, Stanford, CA

The landscape of mucosal melanoma: A long way to go
Jun Guo, Peking University Cancer Hospital & Institute, Beijing, China

Pharmacologic targeting of Gq reveals new pathways in uveal melanoma*
Michael D. Onken, Washington University School of Medicine, St. Louis, MO

12:30 p.m.-3:00 p.m.  POSTER SESSION B AND LUNCH
Liberty Hall 2345

*Short talk from proffered abstract.
SESSION 6: TARGETING DRIVER PATHWAYS BEYOND BRAF
Salons AB

Session Chair: Marcus W. Bosenberg, Yale University School of Medicine, New Haven, CT

Defining the actionable genome
David B. Solit, Memorial Sloan Kettering Cancer Center, New York, NY

Therapeutic opportunities gleaned from melanoma’s unique pathogenesis
David E. Fisher, Massachusetts General Hospital, Boston, MA

Role of autophagy in cancer
Eileen P. White, Rutgers-The Cancer Institute of New Jersey, New Brunswick, NJ

Identifying new immune targets in malignant melanoma
Marcus W. Bosenberg

BREAK
Grand Ballroom Foyer

SPECIAL SESSION: PROFFERED TALKS FROM HIGHLY RATED ABSTRACTS
Salons AB

Session Chairs: Mario Sznol, Yale Cancer Center, New Haven, CT, and Jedd D. Wolchok, Memorial Sloan Kettering Cancer Center, New York, NY

Understanding the role of myddosome dynamics in melanoma using live cell imaging*
Bridget Kreger, AstraZeneca, Waltham, MA

Regulation of the tumor-suppressive miR-29 family by oncogenic MAPK signaling in melanoma*
Olga Vera, Moffitt Cancer Center, Tampa, FL

PTPN11 plays oncogenic roles and is a therapeutic target for BRAF wild-type melanomas*
Minjung Kim, University of South Florida, Tampa, FL

Defining isoform-specific roles for AKTs in BRAFV600E-driven melanoma*
Jaymes Farrell, Tufts University, Boston, MA

*Short talk from proffered abstract.
CONFERENCE PROGRAM

Friday, January 18

7:00 a.m.-8:00 a.m.  CONTINENTAL BREAKFAST
Liberty Hall 2345

8:00 a.m.-10:00 a.m.  SESSION 7: INTERSECTION OF THE TUMOR AND IMMUNE MICROENVIRONMENT
Salons AB

Session Chair: Suzanne L. Topalian, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD

Translating immunotherapy from melanoma to other skin cancers
Suzanne L. Topalian

Intrinsic tumor genomic and metabolic factors leading to immunoresistance
Patrick Hwu, The University of Texas MD Anderson Cancer Center, Houston, TX

Myeloid cell melanoma interface
Karolina Palucka, The Jackson Laboratory, Farmington, CT

CD74 regulated inflammatory pattern is associated with TIL growth and favorable response to adoptive immunotherapy*
Suhendan Ekmekcioglu, The University of Texas MD Anderson Cancer Center, Houston, TX

Specific activation of the G protein-coupled estrogen receptor inhibits melanoma and other cancers and potentiates immune and targeted therapies*
Todd Ridky, University of Pennsylvania, Philadelphia, PA

10:00 a.m.-10:30 a.m.  BREAK
Grand Ballroom Foyer

10:30 a.m.-12:30 p.m.  SESSION 8: BRAF AND MEK RESISTANCE
Salons AB

Session Chair: Jeffrey A. Sosman, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL

Are there nonimmune targets in the BRAF V600 WT melanoma patient?
Jeffrey A. Sosman

Targeting MEK1/2 inhibitor resistance in RAS-mutated cancers
Martin McMahon, University of Utah Huntsman Cancer Institute, Salt Lake City, UT

Strategies to overcome MAPK inhibitor resistance
Roger S. Lo, University of California, Los Angeles, Los Angeles, CA

Sleeping Beauty mutagenesis reveals a Src-dependent DBL GEF family signaling mechanism driving MAPK inhibitor resistance in BRAF mutant melanoma*
Christopher S. Stipp, University of Iowa, Iowa City, IA

Comparative screening of skin-derived NCSCs, melanocytes, and melanoma developmental programs reveals LPAR1 in MAPKi resistance*
Vito W. Rebecca, The Wistar Institute, Philadelphia, PA

*Short talk from proffered abstract.
12:30 p.m.-12:45 p.m.  
CLOSING REMARKS  
Salons AB  
Elizabeth A. Grimm, The University of Texas MD Anderson Cancer Center, Houston, TX  
Mario Sznol, Yale Cancer Center, New Haven, CT  
Jedd D. Wolchok, Memorial Sloan Kettering Cancer Center, New York, NY